SPG15 HSP disease mechanism defined
Drug candidates for treatment identified
HSP Research Foundation
Welcome to the HSP Research Foundation – created in 2005 to find an effective treatment for the Hereditary Spastic Paraplegias (HSPs) – a group of progressive, inherited, degenerative diseases affecting mainly the legs, causing spasticity, muscle weakness and severely impairing walking.
The HSP Research Foundation is an incorporated, registered Australian charity that facilitates and funds research to find effective treatments and cures. The Foundation is also the community hub for people with HSP in Australia, creating awareness and providing information, education and support. Read more »
Summer Edition 2022
Autumn edition to be published early March 2023
Research highlights »
Vast differences in SPG4 HSP explained
Disruption to another gene SARS2 identified
Predicting disease onset in SPG4 HSP
Particular features of gait identified
Promising gene therapy developed
Effective for DNM2 related diseases including SPG
Detailed study of SPG15 HSP
Comprehensive characterisation established
Calcium balance disrupted in SPG4 HSP
Relevant to disease mechanism
Clinical gait analysis tells HSP from CP
Machine learning the key
RNA technologies for neurodegenerative diseases
Advantages and challenges
SPG87 mechanism findings
Lipid processing, ER & mitochondria involved
New HSP genotypes and phenotypes
Research from USA, Germany, Brazil, UK, China, Taiwan, Iran, Azerbaijan, Pakistan
Living with HSPmanagement & treatment news »
Newly diagnosed with HSP?
What you wished you knew
6 commentsSeated Exercise at Home
A ‘view anytime’ webinar
Growing through the hard times
A community member’s story
Getting started with water exercise
And sticking with it to reap the benefits
Annual HSP Survey 2022
All with HSP invited to take the survey
Urinary tract infections and HSP
Option to antibiotic treatment
National Disability Advocacy Program
What supports are available
Innovative mobility device
Flexible configurations for standing or sitting
Foundation News »
Gene therapy access and affordability
Addressing the challenge globally
Kurt Fearnley appointed NDIA Chair
Disabilty advocate Graeme Innes on the board
NDIS update
Concerns Robo-debt coming to NDIS
Progress on HSP gene therapies
SPG4 and SPG56 research
Community member socials
Held in Victoria, Qld, NSW & ACT
Annual General Meeting
Committee elections
Disability Royal Commission
Heartbreaking evidence heard
Gene therapy development for AP-4 HSPs
Manufacturing collaboration announced
HSP Newslink
Newsletter of the HSP Support Group (UK)
